ViewRay Incorporated

258 articles about ViewRay Incorporated

• ViewRay Launches Phase III Pancreatic Cancer Study to Demonstrate Superior Overall Survival for Patients Receiving MRI-guided Ablative Radiation Therapy

  10/18/2022

  ViewRay, Inc. announced the launch of a phase III randomized controlled trial titled "Locally Advanced Pancreatic cancer treated with ABLAtivE stereotactic MRI-guided adaptive radiation therapy" – also known as LAP-ABLATE.

• SUNY Upstate Cancer Center Chooses ViewRay's MRI-Guided Radiation Therapy System to Treat Cancer Patients

  10/6/2022

  ViewRay, Inc. announced that SUNY Upstate Cancer Center in Syracuse, New York has selected MRIdian MRI-Guided Radiation Therapy System and will be the first in Upstate New York to offer the precision of MRIdian's advanced MRI-guided radiation therapy to cancer patients throughout the region for pancreas, prostate, lung, liver, breast, and oligometastatic cancers.

• San Pietro Fatebenefratelli Hospital Treats its 1,000th Patient with MRIdian® MRI-Guided Radiation Therapy

  10/4/2022

  ViewRay, Inc. announced that San Pietro Fatebenefratelli Hospital in Rome has treated its 1,000th patient with MRIdian® MRI-guided radiation therapy.

• ViewRay to host Investor Day

  10/3/2022

  ViewRay, Inc. (NASDAQ: VRAY) announced today plans to host an Investor Day on Thursday, November 17, 2022 , at 8:00 a.m. Eastern Time in New York City , NY.

• MD Anderson Cancer Center Selects ViewRay to Expand MR-Guided Radiation Therapy Program

  9/20/2022

  ViewRay, Inc. announced that the University of Texas MD Anderson Cancer Center in Houston, Texas purchased a MRIdian® MR-Guided Radiation Therapy System.

• ViewRay® to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

  9/9/2022

  ViewRay, Inc. announced that the Company will present at the Morgan Stanley 20th Annual Global Healthcare Conference.

• GenesisCare Purchases Two Additional ViewRay MRIdian MRI-guided Radiotherapy Systems for Guildford and Birmingham Projects, Doubling United Kingdom Footprint to Four Systems

  9/8/2022

  ViewRay, Inc. announced that GenesisCare, the largest global provider of cancer services across the USA, UK, Spain and Australia, has purchased two additional MRIdian MRI-guided radiation therapy systems for installation at new-build comprehensive cancer centres in Guildford and Birmingham.

• ViewRay Announces China NMPA Approval of its MRIdian® MRI-Guided Radiation Therapy for Cancer Patients

  9/7/2022

  ViewRay, Inc. announced that the company's MRIdian MRI-Guided Radiation Therapy System has received approval from the Chinese regulatory authority National Medical Products Administration, allowing for its sale and utilization throughout China.

• VA Houston Healthcare System Selects ViewRay to Expand Advanced Radiation Therapy Services

  8/23/2022

  ViewRay, Inc. announced that the VA Houston Healthcare System has selected a MRIdian MRI-guided radiation therapy system to expand radiation therapy services at the Michael E. DeBakey VA Medical Center.

• National Cancer Center Hospital in Tokyo Upgrades to MRIdian® Linac for MRI-Guided Radiation Therapy and has treated its first patients

  8/11/2022

  ViewRay, Inc. announced that the National Cancer Center Hospital of Japan has upgraded its original Cobalt MRIdian® MRI-Guided Radiation Therapy System to the MRIdian Linac System and has treated its first patients.

• ViewRay Selects Denver for Headquarters

  8/8/2022

  ViewRay, Inc., a medical device company that designs, manufactures, and markets the MRIdian® radiation therapy system, announced that it is moving its headquarters to Denver, Colorado as it continues to attract top-tier talent from the state's growing medical technology sector.

• ViewRay Announces Second Quarter 2022 Results

  8/2/2022

  ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the second quarter ended June 30, 2022.

• ViewRay and Katie Couric Media Partner to Raise Awareness about MRIdian® MRI-Guided Radiation Therapy

  8/2/2022

  ViewRay, Inc, the U.S. maker of the MRIdian System, today announced a partnership with award-winning journalist and cancer advocate Katie Couric's multi-media company, Katie Couric Media ("KCM").

• Centre Oscar Lambret Selects ViewRay's MRIdian® MRI-Guided Radiation Therapy System

  7/29/2022

  ViewRay, Inc. (NASDAQ: VRAY) today announced that Centre Oscar Lambret has selected a MRIdian MRI-Guided Radiation Therapy System.

• ViewRay Announces Conference Call for Second Quarter 2022 Financial Results to be Held After Market on August 2, 2022

  7/19/2022

  ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its first quarter 2022 financial results.

• Saitama Medical University International Medical Center Selects MRIdian® MRI-Guided Radiation Therapy System

  7/19/2022

  ViewRay, Inc. (NASDAQ: VRAY) today announced that Saitama Medical University International Medical Center has purchased a MRIdian MRI-Guided Radiation Therapy System to complete its newly built comprehensive cancer center in Yamane, Hidaka-City.

• Shin-Matsudo Central General Hospital Select's ViewRay's MRIdian® MRI-Guided Radiation Therapy System to Expand Access to Precision Radiation Therapy

  6/7/2022

  ViewRay, Inc. announced that Shin-Matsudo Central General Hospital has purchased a MRIdian MRI-guided radiation therapy system for installation at Shin-Matsudo Accuracy Radiation Therapy Center in Japan.

• Clinical Value of MRIdian® MRI-Guided Radiation Therapy in the Treatment of Ultracentral/Central Lung Tumors Presented at ESTRO 2022

  5/10/2022

  ViewRay, Inc. announced the results of a study presented at the Annual Meeting of the European Society for Radiotherapy and Oncology.

• MRIdian Clinical and Research Experience Featured in Nearly 40 Abstracts at ESTRO 2022, the Leading European Radiation Oncology Meeting

  5/6/2022

  ViewRay, Inc. announced that the company's MRIdian MRI-guided radiation therapy system will be featured at the Annual Meeting of the European Society for Radiotherapy and Oncology, with nearly 40 presentations and posters highlighting MRIdian clinical and research experience.

• ViewRay Announces First Quarter 2022 Results

  5/5/2022

  ViewRay, Inc. announced financial results for the first quarter ended March 31, 2022.